Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 11, keine Gesamtzahl für „substrate“
Suchtreffer
Begriffe & Kennungen
Emselex · 4.5 · CYP3A4 substrates Darifenacin treatment resulted in a modest increase in the exposure of the CYP3A4 substrate
Eintrag öffnenEmselex · 4.5 · Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of th
Eintrag öffnenEmselex · 4.5 · Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of th
Eintrag öffnenEntecavir Accord · 4.5 · Entecavir is not a substrate, an inducer or an inhibitor of cytochrome P450 (CYP450) enzymes (see section 5.2)
Eintrag öffnenEntresto · 4.5 · OATP1B1 and OATP1B3 substrates, e.g. statins In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1
Eintrag öffnenEntresto · 4.5 · OATP1B1 and OATP1B3 substrates, e.g. statins In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1
Eintrag öffnenEnyglid · 4.5 · Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transpo
Eintrag öffnenEnyglid · 4.5 · Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4 substrates
Eintrag öffnenEnzalutamide Viatris · 4.5 · BCRP substrates At steady-state, enzalutamide did not cause a clinically meaningful change in exposure to the
Eintrag öffnenEnzalutamide Viatris · 4.5 · CYP1A2 and CYP2C8 substrates Enzalutamide (160 mg once daily) did not cause a clinically relevant change in th
Eintrag öffnenEnzalutamide Viatris · 4.5 · MRP2, OAT3 and OCT1 substrates Based on in vitro data, inhibition of MRP2 (in the intestine), as well as organ
Eintrag öffnenEnzalutamide Viatris · 4.5 · P-gp substrates In vitro data indicate that enzalutamide may be an inhibitor of the efflux transporter P-gp. A
Eintrag öffnenEpclusa · 4.5 · Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP. Velpatasvir is also a substrate
Eintrag öffnenEpclusa · 4.5 · Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP. Velpatasvir is also a substrate
Eintrag öffnenEpidyolex · 4.5 · Cannabidiol is a substrate for UGT1A7, UGT1A9 and UGT2B7. No formal drug-drug interaction studies have been co
Eintrag öffnenEpidyolex · 4.5 · Everolimus Coadministration of cannabidiol (12.5 mg/kg twice daily) with the P-gp and CYP3A4 substrate everoli
Eintrag öffnenEpidyolex · 4.5 · Sensitive CYP2B6 substrates Coadministration of cannabidiol (7.5 mg/kg twice daily) with a single dose of bupr
Eintrag öffnenEpidyolex · 4.5 · Sensitive CYP2C19 substrates In vitro data have demonstrated that cannabidiol inhibits CYP2C19, which may caus
Eintrag öffnenEpidyolex · 4.5 · Sensitive CYP2C8 substrates Because of potential inhibition of enzyme activity, dose reduction of substrates o
Eintrag öffnenEpidyolex · 4.5 · Sensitive CYP2C9 substrates Coadministration of cannabidiol (7.5 mg/kg twice daily) with a single dose of tolb
Eintrag öffnen